Medical Chronobiology Laboratory - Papers

(All papers are in .pdf format and therefore will need Adobe Reader to be opened, the essays are in html format and will open in a new browser window.)

1986-1990: >back to top of page
1986	1987	1988	1989	1990
062 Antiemetic effect of high-dose metoclopramide	079 Programmable automatic drug delivery	088 Circadian susceptibility-resistance cycles to radiation and their manipulability	113 Sources of variability in dihydropyrimidine dehydrogenase activity	Outpatient time-specified infusion
063 Circadian pharmacodynamics of cyclosporine in rats and man.	080 The importance of proper circadian timing of cancer chemotherapy.	089 Sources of predictable tumor marker variation	114 Local prednisolone infusion of canine renal allografts.	132 Circadian-based infusional FUDR therapy.
064 Programmed automatic FUDR chronotherapy improves therapeutic index	081 Long-term control of locally advanced transitional cell bladder cancer...	090 Profound circadian stage dependence of mitomycin-c toxicity	115 Local immunosuppression with reduced systemic toxicity	134 Circadian variation of new cardiac hormones
065 Automatic chronotherapy using an implanted programmable pump	082 Circadian pattern of continuous FUDR infusion reduces toxicities	091 Sources of variability of dihydropyrimidine dehydrogenase activity	116 Circadian characteristics of dialyzable and non-dialyzable human urinary electrolytes	135 The circadian rhythm of the N-terminus and C-terminus
066 Circadian stage dependence of FUDR toxicity.	083 Rythmes biologiques et marqueurs tumoraux chez l'homme	092 The chronopharmacokinetics of cyclosporine	117 F+63.easibility of vascular catheter placement	136 Circadian reference data for men in fifth decade of life.
067 Chemotherapy-induced vomiting	084 High-dose intensity systemic therapy of metastatic bladder cancer.	093 Circadian rhythm and seasonal dependence	118 Menstrual history and breast cancer surgery	137 Circadian timing of recombinant human erythropoietin
068 Circadian drug schedule affects drug toxicity...	085 High dose intensity, circadian timed, doxorubicin-cisplatin...	094 Increased evening exposure to cyclosporine and metabolites	119 The pharmacokinetic advantage of local 6-mercaptopurine infusion	138 Enhancement of respiratory sinus arrhythmia
069 The respiratory sinus arrhythmia	086 A case for clinical concentration upon the ultradian frequency domain	095 Circadian timing and mode of fluoropyrimidine administration	120 Liposomal formulation eliminates acute toxicity	139 Circadian stage dependent response
070 Cisplatin chronotherapy and disulfiram	087 Timing may be a critical factor in drug therapy.	096 Progressive metastatic renal cell carcinoma	121 Implantable delivery systems: the ultimate home care	140 Fluoropyrimidine pharmacokinetics
071 Cancer-associated alteration of circadian rhythms		097 Estrous influence on surgical cure of a mouse breast cancer.	122 Splenocyte natural killer cell activity	141 Chronobiology of cancer therapy
072 Circadian rhythms in human carcinoembryonic antigen		098 Seasonal Variations of host resistance and in vitro antibody formation of spleen cells from the B6C3F1 mouse.	123 Control of a murine plasmacytoma	142 Determination of the therapeutic index
073 Chemotherapy via implanted infusion pump		099 Ten-year replicated circadian profiles	124 Preclinical and clinical cancer chronotherapy.	143 Chronobionet
074 Advanced transitional cell bladder cancer		100 The rationale for non-zero-order drug delivery	125 Circadian chronotherapy	144 Oral temperature rhythmometry
075 Circadian CEA variability		101 Time-dependent disposition of cyclosporine after pancreas transplantation	126 Menstrual influence on surgical cure of breast cancer.	145 Circadian rhythm alterations
076 Circadian dependency of vinblastin toxicity		102 Circadian-based infusional chrono-chemotherapy	127 Circadian stage not time of day characterizes doxorubicin susceptibility rhythm	146 Pharmacodynamics of local heparin infusion
077 Timing of amphotericin B therapy		103 Splenocyte natural killer cell activity...	128 Automatic chronotherapy	147 Menstrual influence on surgical cure of breast cancer
078 Single cosinor analysis of vaginal smear cell types		104 Two-dose chronopharmacokinetic optimization of cyclosporine...		148 Cancer chemotherapy
		105 An implantable pump for intrarenal infusion		149 More evidence for circadian rhythm effects
		106 Cronoterapia infusionale mediante sistemi automatici		150 Circadian shaped infusions of FUDR
		107 Rationnel de l'administration des medicaments		151 Health care for US veterans and others
		108 Methylene blue protects intestinal mucosa from sublethal radiation damage.		152 Menstrual status and breast cancer surgery-reply
		109 Natural killer cell activity		153 Local immunosuppression of the vascularized graft.
		110 Automatic chronotherapy		154 Cancer chronotherapy and drug delivery systems
		111 Feasibility, safety and accuracy of an automated drug delivery system		155 Reduction of hepatic toxicity by circadian modification
		112 Circadian-shaped intrarenal cyclosporine delivery.		156 Circadian timing and toxicity.
				157 5 Time specified delivery of chemotherapy

1991-1995 >back to top of page
1991	1992	1993	1994	1995
158 5 Time specified delivery of chemotherapy	173 Estimated costs of continuous infusion chemotherapy.	187 Circadian hematopoietic growth factor chronotherapy.	196 Cancer and time.	210 Cisplatin-associated anemia
159 Murine cardiovascular function during pregnancy	174 A pharmacist's primer on chronotherapeutics.	188 Breast cancer and the menstrual cycle	197 The impact of formulated Interleukin-2/delivery device	211 Biological perspectives on circadian cancer therapy.
Revue Europeenne de Technologie Biomedicale	175 Chrono-chemotherapy	189 Diminishing breast cancer chemotherapy	198 Chronopharmacodynamics of hematopoietic growth factors	212 Erythropoietin usage in patients with cancer.
160 Reprogramming SynchroMed pumps	176 Chronotherapy of cancer	190 Chronobiology	199 Protein-surface interactions lead to incomplete delivery	213 Square pegs in round holes
161 What is the impact of the menstrual cycle...	177 Optimal timing of initial breast cancer surgical	191 Circadian cancer pharmacodynamics.	200 Cancer chronotherapy	214 Menstrual cycle timing of breast cancer resection
162 Diminishment of respiratory sinus arrhythmia	178 Circadian cancer chemotherapy	192 Cancer: when in the day to treat.	201 Preclinical trials of cancer chronotherapy.	215 Circadian Anticancer Treatment
163 Temporally optimizable delivery systems	179 Leucovorin-FUDR-Cisplatin-Interferon	193 Circadian pharmacodynamics of anticancer therapies.	202 The Department of Veterans Affairs’ unique clinical cancer research effort.	216 Steroid-responsive interstitial lung disease
164 Evidence for circadian dependency	180 Circadian modification of intra-arterial FUDR	194 Circadian Cancer Chronotherapy.	203 Circadian dynamics of tumor necrosis factor	217 Preface: Larry Scheving and cancer chronotherapy.
165 Quantitative respiratory sinus arrhythmia analysis	181 Chrono-chemotherapy.	195 Circadian cancer therapy.	204 Epilogue: implications of rhythmic biodynamics	218 Cancer chronotherapy
166 Chemotherapy, circadian timing and nutrition	182 Chronoterapie maligních Onemocnêní.		205 Timing is everything.
167 Timing of surgery in breast cancer	183 Mizoribine pharmacokinetics and pharmacodynamics		206 For autonomy and quality, consider a national health service.
168 Temporally optimizable delivery systems	184 The application of chronobiology to cancer medicine.		207 Fluoropyrimidine cancer chronotherapy.
The multifrequency (circadian, fertility cycle and season) balance	185 Infusional chrono-chemotherapy for cancer.		208 Mammography and the menstrual cycle
170 Intra-arterial infusion of immunosuppressants	186 Theoretical and practical implications of circadian pharmacodynamics		209 Introduction: cancer and time.
171 Circadian rhythm of cellular proliferation
172 The effect of surgical timing
129 Principles of chemotherapy and immunotherapy

1996-2000 >back to top of page
1996	1997	1998	1999	2000
219 Circadian timing of cancer chemotherapy.	226 Cisplatin-associated anemia (pp3-5)	234 Triumph of the Trivial	241 The glaspy/cavill article reviewed	247 Investigation of the comparative toxicity of 5-FU
220 Circadian pharmacodynamics.	227 Cisplatin-associated anemia (pp23-26)	235 Home-Based Circadian Optimized Cancer Chemotherapy	242 Identification of therapeutic plasma FUDR concentration	248 Circadian Timing of Cancer Chemotherapy
221 Irreversible inactivation of interleukin-2	228 Circadian Time Structure	236 Menstrual timing of breast cancer surgery	243 Fertility maintenance and 5-fluorouracil timing	249 Timing your medical treatments
222 Breast cancer, timing of surgery, and the menstrual cycle	229 Breast cancer, surgery, and the menstrual cycle	237 Distinct circadian time structures	244 Circadian coordination of cancer take and metastatic spread	250 Rhythmic menstrual cycle modulation of breast cancer biology
223 Chao-periodic patterns in the achievement of understanding.	230 Adsorption of a formulated protein on a drug delivery device surface	238 Der operationszeitpunkt beim prän - einfluB auf die prognose?	245 Circadian toxicology	251 Melatonin Cancer Therapy
224 Cosmos, geos, bios, homos.	231 Chronopharmacology and avoidance of anticancer drug toxicity	239 Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation.	246 Circadian iron and erythropoietin availability and marow responsiveness	252 Circadian Organization of Thymidylate Synthase Activity
225 Circadian rhythms and cancer chemotherapy.	232 The Senie Tenser Article Reviewed	240 Lack of major effect of tumor growth and fluoropyrimidine treatment upon maintenance of fertility cycling		253 The temporal organization of life
	233 Human circadian rhythms in antifolate and fluoropyrimidine developmental therapeutics

2001-2005 >back to top of page
2001	2002	2003	2004	2005
254 Premenopausal Status Accelerates Relapse in node positive breast cancer	262 Circadian chemotherapy for gynecological and genitourinary cancers	266 Breast cancer screening: controversies and future directions	270 Menopausal status dependence of early mortality reduction	278 Elevated Prevalence of Hepatitis C Infection in Users of United State Veterans Medical Centers
255 Cisplatin-incorporated polymeric micelles eliminate nephrotoxicity	263 Fertility cycle influence on surgical breast cancer cure	267 Circadian Timing in Cancer Treatment	271 Induced angiogenesis after surgery in premenopausal node-positive breast cancer patients	279 Timing is Everything: Diverse Strategies for Measuring It
256 Wounding from Biopsy and Breast Cancer Progression	264 Letter to the Editor	268 The Relevance of Circadian Rhythms for Human Welfare	272 Letter to the Editor- Re: Melatonin and breast cancer	280 Does Surgery Unfavorably Perturb the “Natural History” of Early Breast Cancer by Accelerating the Appearance of Distant Metastases
257 Timed Delivery	265 Letter to the Editor	269 Equal access to healthcare in the VA system	273 Letter to the Editor	281 Daily coordination of cancer growth and circadian clock gene expression
258 Circadian expression of clock genes in human oral mucosa and skin			274 Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour	282 Sex cycle modulates cancer growth
259 Tumor chronobiology			275 Recent translational research	283 Season, sun, sex and cervical cancer
260 Letter: Breast cancer screening for women aged 40-49 years			276 Correspondence: Response to Response by Kopans, Get the facts straight	284 Sun exposure, sexual behavior and uterine cervical human papilloma virus
261 Modulation of dose intensity in aerodigestive tract cancers			277 Creation of a stable mammary tumor cell line	285 Circadian cancer biology
				286 Breast Cancer Recurrence Dynamics
				287 Cancer growth and spread are saltatory
				289 Does surgery induces angiogenesis in breast cancer?
				290 Comment to Jatoi et al report
				296 Circadian Function in Patients with Advanced Non-small Cell Lung Cancer
				297 Authors Respond to Controversy Surrounding Breast Cancer Study

2006-2010 >back to top of page
2006	2007	2008	2009	2010
292 Developmental Abnormalities in Multiple Proliferative Tissues of Apc Min/+ Mice	301 Enhanced Surgery-Induced Angiogenesis for Premenopausal Women Might Partially Explain Excess Breast Cancer Mortality of Blacks Compared to Whites
294 Correspondence: Sciodemographic determinants of cancer treatment health literacy
299 Effect of screening and adjuvant therapy on mortality from breast cancer
295 Cancer Circadian Clock BMAL-1 Nuclear Translocation Gates WEE1 Coordinating Cell Cycle Progression, Thymidylate Synthase, and 5-Fluorouracil Therapeutic Index
304 Comment to the paper: Rapiti E, et al: Complete excision of primary breast tumour improves survival of patients with metastatic breast cancer at diagnosis

Papers - By Year
1971-1975: >back to top of page
1971	1972	1973	1974	1975
	001 Lymphocyturia In Renal Allograft Rejection.	003 A Murine Renal Cell Carcinoma.	005 Evaluation of Chemotherapeutic Agents In A New Murine Renal Carcinoma Model.
	002 Carcinogenicity of Ethylmethanesulfonate.	004 Investigation of New Renal Tumor Model.	006 The influence of hormone therapy on rats treated with the carcinogen ethylmethanesulfonate.

1976-1980 >back to top of page
1976	1977	1978	1979	1980
007 L-asparaginase activity in acute non-lymphocytic leukemia.	010 Current status of the therapy of advanced renal carcinoma.	012 Platelets in Thrombocythemia.	014 Chronic lymphocytic leukemia in association with a second lymphoproliferative disorder	017 Synthetic adrenocorticotropin for optimizing murine circadian chronotolerance for adriamycin.
008 The "other" asparaginase.	011 Thrombocytopenia induced by low-dose subcutaneous heparin.	013 Subcutaneous heparin-induced thrombocytopenia.	015 Twenty-four hour synchronized chronotolerance of cis-diamminedichloroplatinum (II)	018 Experimental chrono-oncology.
009 Serpentine supravenous 5-fluorouracil hyperpigmentation.			016 Circadian temperature rhythm in LOU rats	019 Time-varying effects in mice and rats of several synthetic ACTH preparations.
				020 Unusual pigmentary changes associated with 5-fluorouracil therapy
				021 Clinical chrono-oncology.

1981-1985 >back to top of page
1981	1982	1983	1984	1985
022 Perspecitves en chronochimiotherapie anticancereuse.	023 Cyclosporine tolerance improved by circadian timing.	031 Adjuvant chemotherapy for transitional cell carcinoma of the urinary bladder	034 Circadian chronopharmacokinetics and chronotoxicology of doxorubicin and cisplatin in human beings with cancer.	047 Biological time structure and some of its implications in cancer medicine.
	024 Cisplatin urinary pharmacokinetics and nephrotoxicity	032 The clinical application of chronobiology to oncology.	035 24-hour mean pulse	048 Utility of non-invasive instantaneous screening test
	025 Circadian stage dependence of cis-diamminedichloroplatinum lethal toxicity in rats.	033 Circadian rhythmicity of polyamine excretion.	036 Circadian mesor of recumbent pulse	049 Medical relevance of rhythmic biological time structure
	026 Bone marrow suppression from doxorubicin and cis-diamminedichloroplatinum		037 The sine-o-graph pulse monitor	050 Methylene blue ameliorates doxorubicin toxicity
	027 Circadian time dependence of cisplatin urinary pharmacokinetics.		038 Peripheral sensory neuropathy and cisplatin chemotherapy.	051 Modifying intracellular redox balance
	028 Lethal nephrotoxicity and hematologic toxicity		039 Selected aspects of cisplatin nephrotoxicity in the rat and man.	052 Marker rhythms for cancer chrono-chemotherapy.
	029 Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian timing.		040 The effect of anticancer drug timing upon therapeutic index	053 Circadian timing of cancer chemotherapy.
	030 Circaseptan aspects of murine nephrotoxicity of cisdiamminedichloroplatinum		041 Chemotherapy timing	054 Distinguishing between renal allograft and cyclosporine nephrotoxicity.
			042 The respiratory sinus arrhythmia as an objective measure of cardiac age	055 The effect of anticancer drug timing upon therapeutic index.
			043 Lack of age-dependent cisplatin nephrotoxicity.	056 Cyclosporine timing and kidney damage.
			044 Diurnal variation in glucose levels can impede single rate continuous intravenous insulin therapy.	057 Hormonal and chemotherapeutic treatment of prostatic carcinoma
			045 Plasma carcinoembryonic antigen rhythm	058 Cisplatin neurotoxicity
			046 Implantable and extracorporeal programmable drug delivery systems	059 Lack of antiemetic effect of high-dose metoclopramide.
				060 Circadian toxicity of cyclosporine.
				061 Alteration of circadian variation in serum concentrations